{
    "organizations": [],
    "uuid": "09f355b204f9238686c8966df892c4df36dde14f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-kgaa-says-cladribine-tablets/brief-merck-kgaa-says-cladribine-tablets-win-first-approval-in-latin-america-idUSFWN1QG154",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck KGaA Says Cladribine Tablets Win First Approval In Latin America‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Merck KGaA:\n* SAYS MAVENCLAD (CLADRIBINE TABLETS) RECEIVES FIRST APPROVAL IN LATIN AMERICA‍​\n* ARGENTINA'S ANMAT HAS APPROVED REGISTRATION OF CLADRIBINE TABLETS FOR THE TREATMENT OF ADULT PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS Source text: here Further company coverage:\n ",
    "published": "2018-02-27T00:12:00.000+02:00",
    "crawled": "2018-02-27T15:03:46.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "merck",
        "kgaa",
        "say",
        "mavenclad",
        "cladribine",
        "tablet",
        "receives",
        "first",
        "approval",
        "latin",
        "argentina",
        "anmat",
        "approved",
        "registration",
        "cladribine",
        "tablet",
        "treatment",
        "adult",
        "patient",
        "highly",
        "active",
        "relapsing",
        "multiple",
        "sclerosis",
        "source",
        "text",
        "company",
        "coverage"
    ]
}